Kristel Kemper
Overview
Explore the profile of Kristel Kemper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
3156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lloyd K, Middelburg J, Ovcinnikovs V, Pencheva N, Kemper K, van Hall T
Front Oncol
. 2025 Feb;
15:1548446.
PMID: 39995843
CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these...
2.
Middelburg J, Schaap G, Sluijter M, Lloyd K, Ovcinnikovs V, Schuurman J, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800374
Background: CD3 bispecific antibody (CD3 bsAb) therapy has become an established treatment modality for some cancer types and exploits endogenous T cells irrespective of their specificity. However, durable clinical responses...
3.
Middelburg J, Sluijter M, Schaap G, Goynuk B, Lloyd K, Ovcinnikovs V, et al.
Nat Commun
. 2024 Jan;
15(1):48.
PMID: 38167722
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid...
4.
Kemper K, Gielen E, Boross P, Houtkamp M, Plantinga T, de Poot S, et al.
Life Sci Alliance
. 2022 Oct;
5(11).
PMID: 36271507
CD3 bispecific antibodies (bsAbs) show great promise as anticancer therapeutics. Here, we show in-depth mechanistic studies of a CD3 bsAb in solid cancer, using DuoBody-CD3x5T4. Cross-linking T cells with tumor...
5.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd D, Rozeman E, Ibanez Molero S, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5389-5400.
PMID: 34230026
Purpose: Combining anti-PD-1 + anti-CTLA-4 immune-checkpoint blockade (ICB) shows improved patient benefit, but it is associated with severe immune-related adverse events and exceedingly high cost. Therefore, there is a dire...
6.
Middelburg J, Kemper K, Engelberts P, Labrijn A, Schuurman J, van Hall T
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33466732
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces...
7.
Schmidlin T, Debets D, van Gelder C, Stecker K, Rontogianni S, van den Eshof B, et al.
Cell Syst
. 2019 Sep;
9(4):366-374.e5.
PMID: 31521607
Aberrant kinase activity has been linked to a variety of disorders; however, methods to probe kinase activation states in cells have been lacking. Until now, kinase activity has mainly been...
8.
Sanchez I, Purwin T, Chervoneva I, Erkes D, Nguyen M, Davies M, et al.
Mol Cancer Ther
. 2019 Jul;
18(9):1637-1648.
PMID: 31270153
Combined BRAF and MEK inhibition is a standard of care in patients with advanced BRAF-mutant melanoma, but acquired resistance remains a challenge that limits response durability. Here, we quantitated ERK1/2...
9.
Coppe J, Mori M, Pan B, Yau C, Wolf D, Ruiz-Saenz A, et al.
Nat Cell Biol
. 2019 Jun;
21(6):778-790.
PMID: 31160710
Phosphorylation networks intimately regulate mechanisms of response to therapies. Mapping the phospho-catalytic profile of kinases in cells or tissues remains a challenge. Here, we introduce a practical high-throughput system to...
10.
Kluin R, Kemper K, Kuilman T, de Ruiter J, Iyer V, Forment J, et al.
BMC Bioinformatics
. 2018 Oct;
19(1):366.
PMID: 30286710
Background: Mouse xenografts from (patient-derived) tumors (PDX) or tumor cell lines are widely used as models to study various biological and preclinical aspects of cancer. However, analyses of their RNA...